Молекулярно-генетические аспекты внутрипеченочного холангиоцеллюлярного рака: обзор литературы

Обложка

Цитировать

Полный текст

Об авторах

Б. Н. Гурмиков

Национальный медицинский исследовательский центр хирургии им. А.В. Вишневского Минздрава России

Автор, ответственный за переписку.
Email: gurmikov@mail.ru
ORCID iD: 0000-0001-5958-3608

Гурмиков Беслан Нуралиевич.

117997 Москва, ул. Большая Серпуховская, 27.

Россия

Ю. А. Коваленко

Национальный медицинский исследовательский центр хирургии им. А.В. Вишневского Минздрава России

Email: fake@neicon.ru

117997 Москва, ул. Большая Серпуховская, 27.

Россия

В. А. Вишневский

Национальный медицинский исследовательский центр хирургии им. А.В. Вишневского Минздрава России

Email: fake@neicon.ru

117997 Москва, ул. Большая Серпуховская, 27.

Россия

А. В. Чжао

Национальный медицинский исследовательский центр хирургии им. А.В. Вишневского Минздрава России

Email: fake@neicon.ru

117997 Москва, ул. Большая Серпуховская, 27.

Россия

Список литературы

  1. Гришечкина И.А., Викторова И.А., Трухан Д.И., Кондратьева Н.А. Актуальные аспекты диагностики внутрипеченочной холангиокарциномы. Международный журнал прикладных и фундаментальных исследований 2016;11(1):61—5.
  2. Rahnemai-Azar A.A., Weisbrod A.B., Dillhoff M. et al. Intrahepatic cholangiocarcinoma: current management and emerging therapies. Eхpert Rev Gasrtoenterol Hepatol 2017;11(5):439—49. doi: 10.1080/17474124.2017.1309290. PMID: 28317403.
  3. Buettner S., van Vugt J., Ijzermans J.N. Groot Koerkamp B. Intrahepatic cholangiocarcinoma: current perspectives. Onco Targets Ther 2017;10:1131-42. doi: 10.2147/OTT.S93629. PMID: 28260927.
  4. Blechacz B.G., Feldman G.J. Tumors of the bile ducts, gallbladder, and ampulla. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease 2010;1:1171-6. DOI: https://doi.org/10.4143/crt.2015.497. PMID: 24140396.
  5. Jaiswal M., LaRusso N.F., Burgart L.J., Gores G.J. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxidedependent mechanism. Cancer Res 2000;60(1):184-90. PMID: 10646872.
  6. Park J., Tadlock L., Gores G.J., Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 1999;30:1128-33. doi: 10.1002/hep.510300522. PMID: 10534331.
  7. Isomoto H., Kobayashi S., Werneburg N.W. et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005;42(6):1329-38. doi: 10.1002/hep.20966. PMID: 10534331.
  8. Ротин Д.Л. Холангиоцеллюлярная карцинома сегодня. Литературный аналитический обзор. Злокачественные опухоли 2015;3(14):3-16. doi: 10.18027/2224-5057-2015-3-3-16.
  9. Zender S., Nickeleit I., Wuestefeld T. et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell 2013;23(6):784—95. doi: 10.1016/j.ccr.2013.04.019. PMID: 23727022.
  10. Jinawath A., Akiyama Y., Sripa B., Yuasa Y. Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells. J Cancer Res Clin Oncol 2007;133:271-8. DOI:https://doi.org/10.1007/s00432-006-0166-9. PMID: 17294242.
  11. Sirica A.E., Nathanson M.H., Gores G.J., Larusso N.F. Pathobiology of biliary epithelia and cholangiocarcinoma: proceedings of the Henry M. and Lillian Stratton Basic Research Single-Topic-Conference. Hepatology 2008;48(6):2040-6. doi: 10.1002/hep.22623. PMID: 18855901.
  12. Boulter L., Guest R.V., Kendall T.J. et al. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. J Clin Invest 2015;125(3): 1269-85. doi: 10.1172/JCI76452. PMID: 25689248.
  13. Kiguchi K., Carbajal S., Chan K. et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 2001;61(19):6971—6. PMID: 11585718.
  14. Chen M.H., Chiang K.C., Cheng C.T. et al. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. Oncotarget 2014;5(9):2372-89. doi: 10.18632/oncotarget.1706. PMID: 24796583.
  15. Ghouri Y.A., Mian I., Blechacz B. Cancer review: cholangiocarcinoma. J Carcinog 2015;14:1. doi: 10.4103/1477-3163.151940. PMID: 25788866.
  16. Sia D., Tovar V., Moeini A., Llovet J.M. Intrahepatic cholangiocarcinoma: pathgenesis and rationale for molecular thera¬pies. Oncogene 2013;32(41):4861—70. doi: 10.1038/onc.2012.617. PMID: 23318457.
  17. Xu R.F., Sun J.P., Zhang S.R. et al. KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. Biomed Pharmacother 2011;65(1):22—6. doi: 10.1016/j.biopha.2010.06.009. PMID: 21051183.
  18. Borger D.R., Tanabe K.K., Fan K.C. et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad based tumor genotyping. Oncologist 2012;17:72-9. doi: 10.1634/theoncologist.2011-0386. PMID: 22180306.
  19. Kipp B.R., Voss J.S., Kerr S.E. et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol 2012;43:1552-8. doi: 10.1016/j.humpath.2011.12.007. PMID: 22503487.
  20. Oishi N., Kumar M.R., Roessler S. et al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic2012;56(5):1792—803. doi: 10.1002/hep.25890. PMID: 22707408.
  21. Nakaoka T., Saito Y., Saito H. Aberrant DNA methylation as a biomarker and therapeutic target of cholangiocarcinoma. Int J Mol Sci 2017;18(6):1111. doi: 10.3390/ijms18061111. PMID: 28545228.
  22. Limpaiboon T., Khaenam, P., Chinnasri Р. et al. Promoter hypermethylation is a major event of hMLH1 gene inactivation in liver fluke related cholangiocarcinoma. Cancer Lett 2005;217:213-9. doi: 10.1016/j.canlet.2004.06.020. PMID: 15617839.
  23. Liu X.F., Kong F.M., Xu Z. et al. Promoter hypermethylation of deathassociated protein kinase gene in cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2007;6:407-11. PMID: 17690039.
  24. Meng F., Wehbe-Janek H., Henson R. et al. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 2008;27:378-86. doi: 10.1038/sj.onc.1210648. PMID: 17621267.
  25. Pan X.P., Huang L.H., Wang X. MiR-370 functions as prognostic marker in patients with hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 2017;21(16):3581-5. PMID: 28925487.
  26. Hibino S., Saito Y., Muramatsu T. et al. Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells. Oncogenesis 2014;3:104. doi: 10.1038/oncsis.2014.17. PMID: 24861464.
  27. Uhm K.O., Lee E.S., Lee Y.M. et al. Aberrant promoter CpG islands methylation of tumor suppressor genes in cholangiocarcinoma. Oncol Res 2008;17(4):151 —7. PMID: 18773859.
  28. Sirica A.E. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2012;9(1):44—54. doi: 10.1038/nrgastro.2011.222. PMID: 22143274.
  29. Sirica A.E. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol 2008;14(46):7033—58. PMID: 19084911.
  30. Zhang Z., Oyesanya R.A., Campbell D.J. et al. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy. Hepatology 2010;52(3):975—86. doi: 10.1002/hep.23773. PMID: 20607690.
  31. Gruenberger B., Schueller J., Heubrandtner U. et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 2010;11(12):1142—8. doi: 10.1016/S1470-2045(10)70247-3. PMID: 21071270.
  32. Lee J., Park S.H., Chang H.M. et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliarytract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012;13(2):181—8. doi: 10.1016/S1470-2045(11)70301-1. PMID: 22192731.
  33. Moeini A., Sia D., Bardeesy N. et al. Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma. Clin Cancer Res 2016;22(2): 291—300. doi: 10.1158/1078-0432.CCR-14-3296. PMID: 26405193.
  34. Rizvi S., Khan S.H., Hallemeier Ch.L. et al. Cholangiocarcinoma — evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 2018;15(2):95—111. doi: 10.1038/nrclinonc.2017.157. PMID: 28994423.
  35. Borad M.J., Champion M.D, Egan J.B. et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet 2014;10(2):e1004135. doi: 10.1371/journal.pgen.1004135. PMID: 24550739.
  36. Soria J.C., Ohe Y., Vansteenkiste J. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378:113-25. doi: 10.1056/NEJMoa1713137. PMID: 29151359.
  37. Miyamoto M., Ojima H., Iwasaki M. et al. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer 2011;105(1):131—8. doi: 10.1038/bjc.2011.199. PMID: 21673683.
  38. Barat S., Bozko P., Chen X. et al. Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma. Mol Carcinog 2016;55(12):2037—50. doi: 10.1002/mc.22449. PMID: 26757360.
  39. Pant S., Saleh M., Bendell J. et al. A phase I dose escalation study of oral c-MET inhibitor tivantinib(ARQ 197) in combination with gemcitabine in patients with solid tumors. Ann Oncol 2014;25(7): 1416—21. doi: 10.1093/annonc/mdu157. PMID: 24737778.
  40. Wang P., Dong Q., Zhang C. et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 2013;32(25):3091—100. doi: 10.1038/onc.2012.315. PMID: 22824796.
  41. Lim S.M., Yoo J.E., Lim K.H. et al. Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma. Cancer Res Treat 2016;49(1): 185-92. DOI: https://doi.org/10.4143/crt.2015.497. PMID: 27121721.
  42. Davare M.A., Saborowski A., Eide C.A. et al. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc Natl Acad Sci USA 2013;110(48):19519—24. doi: 10.1073/pnas.1319583110. PMID: 24218589.
  43. Xie D., Ren Z., Fan J., Gao Q. Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy. Am J Cancer Res 2016;6(3):577-86. PMID: 27152236.
  44. Ewald F., Grabinski N., Grottke A. et al. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Int J Cancer 2013;133(9):2065—76. doi: 10.1002/ijc.28214. PMID: 23588885.
  45. Costello B.A., Borad M.J., Qi Y et al. Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors. Invest New Drugs 2014;32(4):710—6. doi: 10.1007/s10637-014-0096-3. PMID: 24740268.
  46. Marcus K., Mattos C. Direct Attack on RAS: intramolecular communication and mutation-specific effects. Clin Cancer Res 2015;21(8):1810—8. doi: 10.1158/1078-0432.CCR-14-2148. PMID: 25878362.
  47. Sia D., Hoshida Y., Villanueva A. et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013;144(4):829—40. doi: 10.1053/j.gastro.2013.01.001. PMID: 23295441.
  48. Brierley J.D., Gospodarowicz M.K., Wittekind Ch. TNM classification of malignant tumours. Eighth Edition. 2017. Available at: http://www.hoofdhalskanker.info/wpavl/wp-content/uploads/TNM-Classification-of-Malignant-Tumours-8th-edition.pdf.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ,


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 57560 от  08.04.2014.